1. Introduction
Antibacterial resistance and the dire need for new antibiotics
Due to their short life cycle and ability to adapt quickly to changes in the environment, pathogenic bacteria continue to persist by gradually overcoming the effect of drugs used to eradicate them. This natural phenomenon of drug resistance is often hastened by human practices due to inappropriate use of antibiotics. Currently, more than 70% of pathogenic bacteria are resistant to most antibiotics available in the market and the mortality rate due to bacterial infections is over 2 -million per year, worldwide [1] . The older antibiotic classes discovered more than 50 years ago -still in use after generations of synthetic tailoring -target a limited set of cellular pathways (e.g. cell wall/ protein/folate biosynthetic pathways) or macromolecular structures (DNA-and RNA-protein complexes, ribosomes and enzymes) [2] . Given that for any new antibiotic that enters the market, resistance is observed within years or even months, new drugs with a novel mode of action are needed to avoid cross-resistance (i.e. resistance to a particular antibiotic that often results in resistance to other antibiotics, usually from a similar chemical class, to which the bacteria may not have been exposed). The past thirty years have seen only two truly novel classes of antibiotics entering the market: the oxalidiones (linezolid) and cyclic lipopeptides (daptomycin), for which resistant strains have already emerged [3] . The problem of antibiotic resistance began escalating since the 1980s with a progressive increase in the number of infections due to methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus and fluoroquinolone resistant Pseudomonas aeruginosa. Nevertheless, the number of pharmaceutical companies working on antibiotic research and the number of newly approved antibiotics dwindled sharply by 2010 [4] . The factors which led to only about 4 to 5 pharmaceutical giants to continue their antibacterial research efforts are: antibiotic drug discovery is an expensive, slow and uncertain process with an estimated cost of $800 M per drug developed, time span of 8 to 15 years and with a probability of approval of 1 in a 100 drug candidates (from discovery and preclinical phase to new drug approval) [5] [6] [7] . Antibacterial drugs are not lucrative as they are only used in patients for a short period of time till the infection is cleared. This contrasts with drugs for chronic diseases for which medication is continued through the rest of the patient's lifetime. Lastly, as frequently quoted for antibiotics "the low hanging fruits are already picked" and so it is necessary to put in more effort and adopt novel strategies for finding new antibiotics. Given the alarming increase in multidrug-resistant pathogens, the dearth of new antibiotics and a dry drug-development pipeline, the problem is gaining wide attention and seeks urgent action [8] [9] [10] . A renewed interest in antibacterial research comes from bacterial genome analysis, uncovering~300 highly conserved essential proteins that could serve as broad spectrum targets [11] in contrast to~40 targets exploited so far by most commercial antibiotics [2] . However, finding new drugs against new targets brings in newer challenges [5, 12] .
What is required of an ideal new target?
➢ Any novel antibiotic target should ideally be on the one hand essential, conserved and universal in bacteria and on the other lacking or sufficiently dissimilar or non-essential in humans. Alternatively, targets that are not essential for growth but are required for virulence or pathogenesis are also attractive as they do not impose a strong selection pressure in bacteria that might lead to the development of resistant strains. The idea behind anti-virulence targets is to attenuate the pathogen and facilitate elimination by the host immune system. ➢ The target gene product should be stable in vitro and amenable for high-throughput screens. ➢ Specific targets with known function, structure and properties are desirable in initial drug-discovery efforts. ➢ The cellular location of the target is an important factor as it should be relatively accessible for a potential new drug. ➢ It should be structurally and functionally distinct from a conventional target or site or pathway to avoid cross-resistance.
Why target the bacterial secretion pathway?
More than 30% of bacterial proteins are destined to function at the cell envelope or outside the cell [13] . A vast majority of these proteins with functionally diverse roles such as nutrient uptake, excretion, metabolism, cell structure, communication, virulence and bacterial defense are transported via the ubiquitous Secretion (Sec-) pathway. The Secpathway is essential for viability, universally conserved in bacteria (as well as in the endoplasmic reticulum (ER) of eukaryotes and thylakoid membranes in plants) and is the primary route for protein export. These features and the fact that some Sec-pathway components are not present in eukaryotes make it an attractive target.
The Secretory (or the Sec-) pathway in bacteria
The three primary stages in protein secretion are: targeting to the membrane, translocation across the membrane and the release of the mature protein into the external environment (in Gram-positive bacteria) or the periplasm (in Gram-negative bacteria) (Fig. 1a) . Gram-negative bacteria have additional branches (e.g. Type II and Type V) for protein export across the outer membrane.
Proteins destined to function outside the cytoplasmic membrane are generally synthesized as preproteins with a small N-terminal extension called the signal peptide (SP). Signal peptides, usually found at the amino terminus of secretory proteins, play a decisive role in targeting and transport of preproteins. There are four kinds of signal peptides: Sec-and Tat-type SPs, known as Type I signal peptides, lipoprotein or Type II signal peptides, and Type IV or prepilin signal peptides [14] . Type I SPs have three recognizable regions namely a positively charged amino-terminus (N-region), a central hydrophobic core (H-region) and a neutral, but polar C-terminus (C-region), as shown in Fig. 1b . The hydrophilic C-terminus contains the determinants for recognition and processing by the signal peptidase. Type I SPs interact with components of the Sec-machinery (SecA, SecY and the signal peptidases) [15] and except for Tat SPs (which are less hydrophobic), are thought to delay preprotein folding so as to retain translocation competence [16] . Type II SPs are similar to Type I SPs, but cleavage occurs immediately upstream of a Cys residue, and these are used to target lipoproteins. Type IV SPs differ from conventional N-terminal SPs in that they are usually very short and have no classical tripartite structure [17, 18] .
Targeting of secretory proteins via the Sec-pathway occurs posttranslationally and in a poorly understood non-native state [19] . Some of the newly synthesized preproteins with export signals are recognized and escorted by secretion-specific chaperones, SecB, CsaA or by general chaperones, GroEL and/or DnaK [20] . In E. coli Sec B helps in maintaining 20-30 preproteins in the unfolded, translocation-competent state and targets the bound preprotein to the membrane for translocation. a) Fig. 1a . A schematic representation of the Sec-pathway in E. coli. Preproteins synthesized at the ribosomes are targeted to the membrane translocase, assisted by the cytosolic chaperone, SecB. The Sec-translocase consists of SecYEG protein conducting channel, accessory proteins SecDF (YajC, not shown) and the peripherally associated motor protein, SecA. SecA translocates the preprotein through the channel utilizing the energy from ATP hydrolysis. SPase I, a serine protease, cleaves non-lipoprotein substrates at the extracytoplasmic side, releasing the mature protein. SPase II is an aspartic acid protease which cleaves lipoprotein substrates beneath the extracytoplasmic membrane surface. SPase IV, also an aspartic acid protease, cleaves prepilins and pseudopilins at the cytoplasmic side of the membrane. YidC, a membrane protein insertase, together with the SecYEG channel, inserts membrane proteins via the SRPpathway (not shown). The locations of the N-and C-termini of the membrane enzymes are indicated. The transmembrane helices are depicted as barrels.
Figure adapted in part from [22] .
Translocation of the preprotein via the Sec-pathway (Fig. 1a) involves (i) the SecYEG translocon which is comprised of three integral membrane proteins SecY, SecE and SecG, together forming the protein-conducting channel. (ii) The peripherally associated motor protein SecA, that drives the preprotein through the channel by repeated cycles of ATP binding and hydrolysis. (iii) The accessory heterotrimeric complex SecDFYajC, which closely associates with SecYEG and is predicted to function at the late stage of translocation possibly by pulling the preprotein from the periplasmic side or promoting its folding [21] .
During or shortly after translocation, if applicable, the signal peptide is removed by the signal peptidase (SPase), allowing the release of the mature protein from the membrane. Among the preproteins, the majority (non-lipoproteins) are processed by the Type I SPase (SPase I) while lipoproteins are processed by the Type II SPase (SPase II). Precursors of pilin and related pseudopilins (Section 4.2) are processed by the Type IV SPase (SPase IV) [14, 22] . Subsequently, the mature protein is folded at the trans side of the membrane.
The Sec system (particularly the Sec YEG channel) along with a membrane protein insertase YidC, is also involved in membrane protein insertion but the targeting of these proteins occurs by the signal recognition particle (SRP) pathway (Section 4.3). In addition to the Sec pathway, several bacteria utilize the Twin arginine translocation (Tat) pathway for exporting a subset of proteins (Section 4.2), and although there are differences in the targeting and the translocation apparati, SPases I are common to both Sec and Tat pathways.
Antibiotic targets in the Sec-pathway
The integral membrane proteins SecY and SecE are essential for viability and protein translocation while SecG is not essential but increases translocation efficiency [21] . The SecYEG proteins are universally conserved, homologous to their eukaryotic counterparts Sec61 αγβ and have no enzymatic activity, thus are not ideal targets. Interestingly, indirect targeting of SecY by some antibiotics [23, 24] suggests that there is a potential to exploit such an approach. SecD and SecF are not essential but improve the efficiency of translocation. The two proteins are not present in eukaryotes but are not present in all prokaryotes either [25, 26] . Although not broad-spectrum, SecD and SecF may be exploited as targets as their deletion results in severely reduced protein secretion and growth and both proteins have large, soluble domains protruding on the trans side of the membrane, and would be accessible to potential drugs [26] . YajC (a protein of unknown function) is neither essential for cell viability nor for protein translocation [21, 27] .
SPase I and SecA were the first Sec-pathway components pursued as targets. They are essential in bacteria and attractive as targets for which HTS assays exist and a few inhibitors are already available. Type II signal peptidases, Type IV signal peptidases and YidC are potential candidates that have also been pursued in recent years.
In this review, we summarize the major developments, the current situation and progress of SPase I (Section 2) and SecA (Section 3) as antibiotic targets. We additionally briefly discuss the efforts towards targeting other components of the Sec-pathway as well as the other pathways associated with bacterial protein secretion (Section 4).
2. The Type I signal peptidase (SPase I) as an antibiotic target 2.1. SPase I: properties, structure, mode of action and its relevance as an antibiotic target
The physiological role of the Type I SPase (also known as "leader peptidase") is to release the mature protein from the membrane for it to reach its correct cellular or extracellular destination [28] . Without SPase I activity, the precursors remain membrane-bound due to the uncleaved signal peptide acting as a membrane anchor [29] . Recent studies indicate that the function of SPase I extends beyond secretion and that they probably have a regulatory role as well. For example, the SPase I from S. aureus cleaves and inactivates lipoteichoic acid synthase (LtaS), a membrane embedded enzyme that synthesizes lipoteichoic acid, an important cell envelope component of Gram-positive bacteria [30] .
SPase I (EC 3.4.21.89) is an unconventional serine protease which does not use the canonical Ser/His/Asp triad but instead utilizes a Ser/Lys dyad and is classified into the evolutionary Clan SF, family S26 [31] .
Properties
Gram-negative bacteria (e.g., E. coli, Salmonella Typhimurium) typically have one chromosomally encoded SPase I which is essential and constitutively expressed. One of the exceptions is P. aeruginosa, with two Type I SPases (LepB and PA1303) each with a distinct role in physiology and virulence [32] . Gram-positive bacteria (e.g., Bacillus subtilis and Streptomyces lividans) often have more than one SPase I, of which none of the individual enzymes is essential for cell viability on its own. Exceptions include Streptococcus pneumoniae, Mycobacterium tuberculosis and S. aureus [33] . SPases I are anchored to the membrane by one (typically in Gram-positive) or more amino-terminal transmembrane segments, (typically in Gram-negative bacteria). The carboxy-terminal catalytic domain is significantly smaller in SPases I of Gram-positive bacteria compared to those of Gram-negative bacteria. Despite these minor differences, SPases I contain five regions of high-sequence similarity and identity referred to as boxes A to E, that are common and conserved [29] . Box A consists of hydrophobic residues residing in the membrane spanning regions of the SPases I. Box B and Box D contain the catalytic Ser and Lys residues respectively, while Boxes C and E contain residues important for substrate binding and for positioning of the catalytic residues.
SPase I has substrate specificity for small and neutral residues at − 3 (or P3) and − 1 (or P1) positions relative to the cleavage site [34] (Fig. 1b) . The SPase I recognition motif in the SP is referred to as 'Ala-X-Ala', as a consequence of the frequent presence of Ala residues at these positions. During preprotein translocation, the N-region of the signal peptide acts as the topological determinant by following the 'positive-inside rule' of membrane proteins [35] . The H-region is believed to span the membrane as an α-helix, while the C-region adopts a β-stranded conformation allowing access to the SPase I cleavage site on the periplasmic side and processing [36] . The signal peptides in Gram-negative bacteria are generally shorter than those in Gram- positive bacteria. In case of the former, where the signal peptide is not long enough to span the membrane, the H-region is believed to change from an α-helix to an extended structure in the membrane [22] . Apart from Sec substrates, SPase I processes preproteins with Tat signal peptides (Section 4.3) and a few membrane proteins [22] . An interesting example is the membrane-embedded enzyme LtaS (Section 2.1) with five N-terminal transmembrane helices in which the Ala-X-Ala motif is located not after an N-terminal signal peptide but 44 residues after the last transmembrane domain [30] . For more details about the signal peptide processing by SPases I, see Paetzel M [37] . The biochemical properties of E. coli LepB as well as SPases I from Gram-positive bacteria B. subtilis, S. lividans, S. pneumoniae, (see review [33] ), and S. aureus [38] have been studied in detail. The common in vitro properties of SPase I include: (i) concentration and timedependent, intermolecular-self cleavage leading to inactive fragments, (ii) optimum activity requires non-ionic detergents (such as Triton-X-100), (iii) phospholipids enhance activity and (iv) optimum pH varies from pH 8 to pH 11, in contrast to classical serine proteases.
E. coli LepB is the best characterized among the SPases I [34] . A truncated derivative, Δ2-76 SPase I (previously Δ2-75) lacking residues 2-76 corresponding to the transmembrane segment was designed, purified and characterized in vitro [39, 40] (Note that the E. coli numbering was changed recently [41] owing to a missing residue in the sequencing data. The results remain unaffected as the missing residue is from the cytoplasmic loop region, only the numbering used in the previously reported crystal structures are now up by one number). The Δ2-76 SPase I is active in vitro, but less efficient compared to the full-length SPase I [42] . Crystal structures of the Δ2-76 SPase I in its Apo-form [40, 43] and in the complex with inhibitors [36, 41, 44, 45] have helped in understanding the unique properties of the enzyme.
Structure and mode of action
Crystal structure of E. coli LepB Δ2-76 ( Fig. 2) has a unique mostly β-sheet protein fold, consisting of two antiparallel β-sheet domains, domain I and II. Domain I contains all the conserved regions (boxes B-E) in bacterial SPase I, while domain II (an insertion within domain I) and an extended β-ribbon are mostly limited to Gram-negative bacteria [36] . An unusually large hydrophobic surface that includes the catalytic center and the adjacent substrate binding sites is the proposed membrane association surface (Fig. 2) . This surface, predicted to be in close association with the membrane and capable of inserting into the lipid bilayer during signal peptide cleavage, explains the detergent requirement of the SPase I for optimum activity and crystallization [36] . Two shallow hydrophobic depressions appropriate for accommodating small aliphatic residues form the substrate binding pockets S1 and S3 (Fig. 2) and provide the basis for Ala-X-Ala specificity. Site-directed mutagenesis identified two Ile residues (Ile87 and Ile145, E. coli numbering) in the borderline between the S1 and S3 sites, contributing to the high fidelity and substrate specificity of the SPase I [46] .
Paetzel et al. [14, 34, 37] proposed the proteolytic mechanism of the bacterial SPase I which is illustrated based on current data. Briefly, the SP binds to the SPase I making β-sheet type hydrogen bonding interactions with both β-strands that line the substrate binding sites of the SPase I [44] . The P1 and P3 residues of the SP occupy the S1 and S3 binding pockets of the SPase I, respectively, while P5 and P7 residues occupy potential binding sites S5 and S7, respectively [45] . P2 is solvent exposed which explains the lack of specificity at this position. Upon substrate binding, the -amino group of Lys146 (general base) abstracts a proton from the side chain hydroxyl group of Ser91 (nucleophile) , resulting in the dissociation of the signal peptide and regeneration of the SPase I active site.
Relevance as antibiotic target
SPases I are attractive targets because:
(i) they are ubiquitous and conserved in bacteria.
(ii) SPase I activity is essential for growth and viability in bacteria. This was first demonstrated by genetic [47] and functional studies [48] in E. coli. SPase I inhibition leads to accumulation of preproteins in the cell membrane resulting in cell death [49] . (iii) SPases I differ sufficiently from their eukaryotic counterparts (present in ER and mitochondria of humans) in structure, localization and catalytic mechanism, thereby reducing possibilities for toxicity [14] . Unlike bacterial SPases I which are monomeric, eukaryotic SPases are multimeric complexes, located in the inner membrane of mitochondria or in the lumen of the ER and in the case of the latter, operate by the conventional Ser/His/Asp triad mechanism or Ser/His dyad mechanism. (iv) The Ser/Lys catalytic dyad mechanism and the si-face attack of its substrates (rather than re-face attack used by most Serdependent proteases), characteristic of the SPase I allows selective target inhibition without inhibiting other essential proteases in eukaryotes. (v) The catalytic domain of the bacterial SPase I, exposed to the outer leaflet of the plasma membrane, is accessible to potential inhibitors. (vi) SPase I inhibition is likely to result in simultaneous attenuation due to its role in virulence.
Molecular and functional analyses of the gene encoding SPase I in several bacteria including human pathogens such as S. Typhimurium [50] , S. aureus [51] , S. pneumoniae [52] , Rickettsia rickettsii [53] , Legionella pneumophila [54] , S. epidermidis [55] , P. aeruginosa [32] and M. tuberculosis [56] have confirmed its essential role. SPase I is a suitable target against resistant pathogens requiring urgent medical intervention:
S. aureus, responsible for a wide array of infections (including skin, bone, lung and blood stream) and known for its remarkable ability to develop resistance, has one active and essential SPase I, termed SpsB. The enzyme is characterized in vitro and validated as a target [38, 51] . Several SpsB-dependent proteins required for virulence such as extracellular proteases, lipases, superantigens, haemolysins and leukocidins were identified by secretome profiling of S. aureus [57] . SpsB also plays a role in the agr quorum sensing system, which is important for biofilm formation and virulence [58] . SpsB is also suggested to have a regulatory role due to its proteolytic action resulting in inactivation of LtaS, as discussed in Section 2.1. P. aeruginosa, an opportunistic pathogen, naturally resistant to many frontline antibiotics, has two SPases I, LepB and PA1303, characterized recently. LepB is the essential and primary SPase I, while PA1303 is non-essential with a likely function in the suppression of virulence factor secretion through the quorum-sensing (QS) cascade [32] . In silico analysis predicts 801 P. aeruginosa proteins (14.4% of the genome) as containing putative SPase I substrates. The substrates include components of the Sec-pathway, outer membrane proteins and porins, flagellar structural proteins, cell wall biosynthesis enzymes as well as virulence factors including elastases (LasA and LasB), endotoxin A, β-lactamase and proteins involved in biosynthesis of alginate, suggesting a direct role in house-keeping as well as pathogenesis [32] . S. pneumoniae, responsible for considerable illness (including pneumonia, ear infections and meningitis) and mortality due to drugresistant strains, has one SPase I, Spi. It is also a well characterized and validated target [52, [59] [60] [61] . Listeria monocytogenes, a food-borne pathogen, has three paralogs of SPase I, SipX, SipY and SipZ. Deletion of the sipZ gene (encoding the major SPase I) results in impaired secretion of virulence factors (e.g., listeriolysin O and phospholipase C), rendering it almost avirulent [62] , highlighting the function of SPase I in virulence. S. epidermidis, a common cause of nosocomial infections and biofilm-associated foreign body infections has two active SPases I (Sip2 or SpsIB and Sip3) which are attractive targets not only in free-living but also in biofilm-associated S. epidermidis cells [55] . Consistent with its role in pathogenesis, secretome analysis of SPase I-dependent proteins during stationary growth phase of S. epidermidis, identified 11 proteins including peptidoglycan hydrolases, proteases and lipases, which are important for virulence [63] . M. tuberculosis has one essential Type I SPase, LepB [56] . LepB is a promising target as demonstrated using an SPase I inhibitor (MD3, a beta-aminoketone; see Supplementary Fig. S1 online) which is bactericidal against actively growing cells and even more potent against non-replicating or persistent cells [56] . However, the MD3 inhibitor is not suitable for drug development due to compound instability.
SPase I inhibition assays
The entire range of SPase I assays used at different stages of inhibitor search is summarized below.
In vitro inhibition assays
2.2.1.1. Preprotein processing assay. This assay involves incubation of the purified SPase I and preprotein followed by separation of products by SDS-PAGE [64] . Pro-OmpA-Nuclease A, a hybrid protein of S. aureus nuclease A fused to the signal peptide of E. coli outer membrane protein A (OmpA) [34, 65] , is an excellent substrate for measuring in vitro activity as well as for kinetic analysis of SPase I ( Table 1 ). The assay is gel-based and as such not ideal for HTS of inhibitors although it can be used as a confirmatory assay for SPase I inhibition [38] .
Fluorescent resonance energy transfer (FRET)-based assays.
Synthetic substrates for SPase I are short stretches of residues, identical to those in the signal peptide region of preproteins containing the SPase I recognition and cleavage site. Peptides that are at least 9-mers and in addition have SP-like features incorporated in them are far better substrates. For example, Stein et al. [66] appended K 5 -L 10 to incorporate a positively charged N-terminus and a hydrophobic core, respectively (see Table 2 , substrate 1) whereas Bruton et al. [67] incorporated a decanoyl moiety (mimicking a membrane anchor) and a turn inducing motif (proline at P5 position) as shown in Table 1 (substrate 2) and Table 2 (substrate 4) .
A difference in substrate specificity of SPases I is observed even with the synthetic substrates (see review [68] ). Thus in vitro inhibition assays developed for SPases I from Gram-negative E. coli and Grampositive pathogens, S. pneumoniae, S. aureus and S. epidermidis, involve specifically designed substrates (see Table 2 ). The in vitro assays facilitated the characterization and comparison of SPases I from different bacteria. Often these assays are FRET-based, allowing rapid measurement and some are already optimized for high-throughput screening of inhibitors. The in vitro inhibition assay for S. pneumoniae was used for high-throughput screening of 50,000 pre-fractionated natural product samples [59] , of which only one sample inhibited SPase I. This was identified as lipoglycopeptide or Arylomycin C (Section 2.3.3). We optimized a high-throughput FRET-based assay for S. aureus SpsB and screened~26,000 diverse small molecules (average Z′ value [69] of 0. 73) but did not obtain potent hits [38, 70] . Z′ scores are measures of standard deviation, derived using the formula:
where, σ C+ and σ C− are standard deviations of positive and negative controls, respectively while μ C+ and μ C− are the means of positive and negative controls, respectively. The in vitro efficacy of a rationally designed peptide aldehyde inhibitor (Section 2.3.2) was demonstrated using the SpsB FRET assay [71] .
In vivo assays
The secretion of β-lactamase, a Sec-dependent substrate, is used to gauge in vivo SPase I activity/inhibition. Initially, whole cell pulsechase analysis of processing of pre-β-lactamase to β-lactamase in E. coli was used to demonstrate the inhibition of preprotein processing in situ by a SPase I inhibitor, penem [72] . This test is now replaced by the β-lactamase secretion assay.
2.2.2.1. β-lactamase secretion assay in S. aureus. The assay involves measurement of hydrolysis of nitrocefin, a chromogenic β-lactamase substrate in culture supernatants incubated in the presence and absence of an inhibitor. The assay is used as a secondary assay for SPase I inhibition [59, 73] . Amino acids are abbreviated as single letter codes. The arrow indicates the point of cleavage and P1 and P3 residues are in bold. a A hybrid protein made up of signal peptide of outer membrane protein A from E. coli and the nuclease A from S. aureus.
Target-based whole cell assays
These have an advantage over the assays mentioned above as compounds are tested based on both the mode of action as well as the antibacterial activity. These assays are based on the observation that reduced expression of an essential target gene renders the strain sensitive to compounds that inhibit that particular gene product or pathway.
Regulated expression of SPase I.
A cellular assay employing an E. coli strain underexpressing lepB gene was validated for testing SPase I inhibitors using penem, a known SPase I inhibitor [74] . The strain has E. coli lepB under an arabinose regulatable promoter cloned onto a plasmid while the chromosomal lepB gene has been removed. The assay was used as a secondary assay to test three potential inhibitors derived from HTS in vitro. The inhibitors did not have significant antibacterial activity against E. coli [74] . Recently, one of the inhibitors, MD3, was reported to be active against M. tuberculosis (MIC 99 of 17.7 μM) [56] (Section 2.1.3).
In M. tuberculosis, a lepB overexpression strain showed reduced susceptibility to the aforementioned β-aminoketone inhibitor while the lepB underexpression strain showed increased susceptibility to the inhibitor, validating SPase I as the target [56] .
2.2.3.2.
Bacterial target array -S. aureus fitness test (SaFT) profiling. This is a method to determine the mode of action of a new compound by simultaneous screening against all essential bacterial gene targets. It is based on 245 S. aureus antisense RNA strains, each of which is engineered for reduced expression of (conserved, broad-spectrum) target genes essential for its growth [75] . Briefly, this semi-automated method involves growth of strains in the presence and absence of test compounds, determination of relative abundance of the strains by multiplex PCR, capillary electrophoresis and DNA fragment analysis to quantify strain-specific markers [75, 76] . This strategy adopted by Merck resulted in finding several new classes of natural compounds [11] including inhibitors for the Type I signal peptidases [73] .
Overview of SPase I inhibitors
SPases I are insensitive to classical protease inhibitors including serine protease inhibitors [34] . Based on the observation that there is at least one other enzyme (signal peptide peptidase A) operating with the same Ser-Lys catalytic dyad mechanism that is inhibited by common serine protease inhibitors, Dalbey et al. [22] suggested that serine protease inhibitors do not bind with high affinity to SPase I.
The search for effective inhibitors for SPase I, a challenging task from the start [77] has led to some exciting developments as illustrated below.
Discovery of Penems (β-lactam type inhibitors)
Although the essential role of SPase I in E. coli was demonstrated in the early eighties [47, 48] , the mechanism of action of SPases I remained unclear till the late nineties. Two pharmaceutical companies discovered β-lactam inhibitors of SPase I: monocyclic azetidinones, the first (nonpeptide) inhibitors effective against E. coli LepB albeit at very high concentrations (500 μM) [78] ; and 5 S-Penem stereoisomers, the first potent irreversible inhibitors [79] (Table 3 , inhibitor 1). Extensive in vitro screening and optimization efforts at GlaxoSmithKline (previously SmithKline Beecham) [72, 77, 80, 81] resulted in a few potent inhibitors including allyl (5S, 6S)-6-[(R)-acetoxyethyl]-penem-3-carboxylate (Fig. 3) , with an IC 50 of 0.38 μM against E. coli LepB. Based on the 5S-stereochemistry of the inhibitor, it was proposed that SPase I attacks the peptide backbone of its substrates from the si-face (uncommon for serine-dependent hydrolases) rather than from the re-face. The inhibitor was co-crystallized with the catalytic domain of the SPase I to obtain a high resolution structure that provided a direct proof of SPase I utilizing the Ser/Lys catalytic dyad mechanism [36] . The structure showed that Ser 91 (E. coli numbering) attacks the siface of the β-lactam amide bond which is a peptide bond analog. The crystal structure by Paetzel et al. [34, 36] provides valuable information on the active site, helps explain the unique characteristics of the enzyme and serves as a template for inhibitor design. Despite high in vitro activity, the penem-type inhibitors (Fig. 3) , generally have poor antibacterial activity (Table 3 , inhibitors 1 and 2) likely due to low cell wall penetration or compound instability [77, 82] , limiting their clinical application. A couple of exceptions noted in a recent study are that penem and a carbamate-derivatized penem are moderately effective against S. epidermidis and MRSA, respectively [83] (Table 3 , inhibitors 3 and 4).
Designing peptide, lipopeptide and peptide aldehyde inhibitors
Early studies proved that (i) SPases I are competitively inhibited by signal peptides in vitro [84] . (ii) Preproteins or synthetic substrates with Pro at +1 position inhibit SPase I activity in vivo, leading to an impaired growth of cells [85, 86] . Attempts at designing peptide inhibitors based on the classical approach used for serine protease inhibitors did not work initially for the SPase I [77] till researchers at GlaxoSmithKline finally came up with highly effective lipopeptide inhibitors [67] and a substrate for in vitro inhibition assay (Table 1 , substrate 2). The peptides were based on the consensus sequence of preproteins in S. aureus and designed to incorporate key structural elements of a signal peptide, namely an alkyl membrane anchor, a helix breaking Pro at P5 and a Lys at P2 (for the AKA). Insertion of Pro at + 1 converted the peptide into a competitive inhibitor while incorporation of α-ketoamide at the cleavage site transformed it to a time-dependent inhibitor of S. aureus SpsB (IC 50 of 0.6 and 0.1 μM, respectively) [67] (Table 3 , inhibitors 5 and 6). The antimicrobial activity of the lipopeptide is undisclosed. Further optimization resulted in a lipopeptide aldehyde inhibitor ( Fig. 3 ) with increased potency against SpsB (IC 50 of 0.09 μM) but with poor antimicrobial activity [71] (Table 3 , inhibitor 7). These studies proved the critical role of N-terminal fatty acid for potency of the inhibitor in vitro as well as in vivo. It is presumed that it probably mimics the hydrophobic region of the signal peptides in preproteins. This also explains why peptides as such did not prove to be effective inhibitors. Interestingly, a signal peptide mimic designed and synthesized based on an antimicrobial peptide from Sacrophaga peregrina (flesh fruit fly) inhibits E. coli LepB (IC 50 of 30 μM) and has antibacterial activity against E. coli (MIC = 16 μM), S. aureus (8 μM) and S. pneumoniae (4.8 μM) [87] ( Table 3 , inhibitor 8).
Discovery of natural product Arylomycins
Arylomycins are among the most extensively studied SPase I inhibitors as they are the first inhibitors with significant antibacterial activity. There are currently four related families of arylomycins (including actinocarbasin, Section 2.3.4) identified by independent groups.
Arylomycins (A and B series) were first reported in 2002 with their structure and limited antibacterial activity [88, 89] . Subsequently, the crystal structure of Δ2-76 SPase I in complex with a member, Arylomycin A 2 , revealed their mechanism of action [44] . Lipoglycopeptides (Arylomycin C series) were identified in parallel (by Eli Lilly and Company) as inhibitors of E. coli and S. pneumoniae SPases I in a high-throughput FRET-based assay (Section 2.2.1.2) [59] . Modest antibacterial activity was observed against a few pathogens [59] ( Table 3 , inhibitor 11).
Arylomycins are secondary metabolites from Streptomyces spp., synthesized by nonribosomal peptide synthesis. They are lipohexapeptides with a common core structure consisting of a [3, 3] biaryllinked tripeptide macrocycle at the C-terminus and a fatty acid tail attached to the N-terminus (Fig. 3) . Arylomycin B series differ from A by nitro-substitution of the tyrosine residue (Fig. 3) . Arylomycin C series differ from the A series by glycosylation, and in some cases hydroxylation of the macrocycle and a longer fatty acid tail [59, 90] (Fig. 3) .
Arylomycin A 2 does not inhibit the growth of E. coli, P. aeruginosa and S. aureus, while it is highly potent against S. epidermidis (MIC of 1 μg/ml) [91] (Table 3 , inhibitor 9). In an interesting study, Romesberg et al. [92] demonstrated that S. epidermidis develops resistance to arylomycin by a point mutation (Ser to Pro at residue 29) in SpsIB, one of the two active SPases I. The resistance-conferring Pro is responsible for natural resistance to arylomycins in bacteria such as E. coli, P. aeruginosa and in some strains of S. aureus. The absence of Pro is often predictive of arylomycin sensitivity with only a few exceptions [92] (Table 3 , inhibitor 10). The otherwise broad-spectrum activity of arylomycins was demonstrated using a synthetic derivative with a longer fatty acid tail (Arylomycin A-C 16 ) [92] . In fact its potency against a few coagulase- negative staphylococci (Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis) is equal to or greater than that of vancomycin, commonly prescribed for treatment of MRSA [93] . The molecular basis for resistance was provided by the crystal structure of arylomycin in complex with the E. coli SPase I [44] which shows that the resistance-conferring Pro residue is present in a less conserved region of the SPase I (away from the catalytic center but within the substrate binding pocket) with which arylomycin interacts [92] . The mutation reduces the binding affinity of arylomycin with the SPase I. Chemical synthesis of arylomycins (A, B and C series) and their derivatives have facilitated structure-activity relationship (SAR) studies (see review [90] ). Synthetic arylomycin derivatives (with methylene units in the arylomycin backbone) designed to compensate for the unfavorable interactions caused by the resistance-conferring Pro, restored some activity against wild-type S. aureus [90] . Thus, arylomycins are natural antibiotics for which resistance has evolved and so their broad-spectrum activity is more likely to be restored by synthetic tailoring compared to molecules that have never been antibiotics [90] . The crystal structure data provides additional possibilities for optimizing the arylomycin scaffold.
Arylomycin A 2 binds non-covalently to the SPase I in a manner thought to mimic its natural substrates. The inhibitor position in the binding pocket with its C-terminal tripeptide macrocycle points towards the active site and makes a parallel β-strand interaction with β-strand that lines the SPase I binding cleft. The methylene groups of the C 12 fatty acid make Van der Waals interaction with the predicted membrane association surface of the SPase I. This provides a rationale for the critical role of amino-terminal fatty acid for effectiveness of SPase I inhibitors and substrates. SAR studies in arylomycin indicate that a minimum of C 12 tail is required and those up to C 16 are ideal [90] . The crystal Fig. 3 . Chemical structures of SPase I inhibitors indicated in Table 3 . structure of arylomycin in ternary complex with the SPase I and a weak inhibitor, morpholino-β-sultam derivative (BAL0019193; see Supplementary Fig. S1 online) also suggests a scope for further optimization. The β-sultam derivative binds noncovalently at the active site, taking a parallel orientation relative to the biaryl ring moiety of arylomycin, defining a novel space that can be occupied by optimizing the arylomycin scaffold [45] (Fig. 2) . The structure of SPase I in complex with a lipoglycopeptide (arylomycin C) derivative shows that the sugar moiety is directed away from the binding site, suggesting that other modifications may be made at this position to possibly optimize the pharmacokinetics of the scaffold [41] . A recent study showed that C-terminal homologation with a glycyl aldehyde and the addition of a positive charge to the macrocycle increase the activity and spectrum of arylomycin [94] .
A study used model strains of E. coli and S. aureus (with a point mutation to remove the resistance-conferring Pro) to demonstrate that the antibiotic activity of arylomycins is a result of insufficient SPase I activity and it can be either bacteriostatic or bactericidal, depending on the organism and growth conditions [95] . In addition, arylomycins show relatively little synergy or antagonism with most other antibiotic classes with the exception of gentamicin, an aminoglycoside, with which it shows synergy (Table 4 ).
Discovery of actinocarbasin and krisynomycin
Actinocarbasin and krisynomycin are structurally distinct, natural products with significant antimicrobial activity, identified by a reverse genomic approach [73] . This approach (also sometimes referred to as compound-driven target identification, chemical biology, or chemical genetics), is to screen for compounds with antibacterial whole cell activity and then determine their mechanism of action using various biochemical and genetic approaches. Imipenem (a carbapenem) is a highly successful β-lactam antibiotic which is ineffective against MRSA. To find potentiators of imipenem (a second agent added to fight specific resistance to imipenem) against MRSA, a high-throughput, MRSA agar growth assay was used to screen molecules derived from microbial extracts [73] . This led to identifying krisynomycin (a cyclic depsipeptide) isolated from Streptomyces fradiae strain MA7310 and actinocarbasin (a lipoglycopeptide) from Actinoplanes ferrugineus strain MA7383. The two molecules potentiate the activity of imipenem at a concentration 16-fold below their native MIC value (Table 3, inhibitors 12 and 14) . An optimized synthetic derivative of actinocarbasin, M131 (Fig. 3) has improved potency and synergy with imipenem (Table 3 , inhibitor 13). The cellular target of actinocarbasin, M131 and krisynomycin was identified as the SPase I, SpsB, by S. aureus fitness test profiling (Section 2.2.3.2). Their potency was confirmed in a FRET-based assay (Section 2.2.1.2) and β-lactamase secretion assay (Section 2.2.2.1).
Actinocarbasin has the same core macrocycle as the arylomycins but with O-sulfonation on the aryl rings and extensive modification of the lipopeptide tail (Fig. 3) , and hence recently grouped into the arylomycin D series [90] . Krisynomycin (Fig. 3) belongs to a new structural class.
Synergy of the molecules with imipenem against MRSA clinical isolates was demonstrated using the checkerboard method [73] ( Table 4) . Thieren et al. [73] demonstrated that the synergy of the SPase I inhibitors is specific to the β-lactam class (including penicillins, cephalosporins and carbapenems, except for ceftazimide) and not for any other classes of antibiotics tested and specific for MRSA. Synergy of M131 with imipenem is also effective in vivo, in murine models of MRSA infection; and importantly, combining imipenem with SPase I inhibitor M131 suppresses the emergence of M131 resistance.
β-lactams are the most successful antibiotics for treatment of bacterial infections caused by numerous species, spanning 60 years and representing over 65% of the world antibiotic market [96] . Given that, combination therapy is expected to account for the most common use of the β-lactams in future [96] , the synergy of β-lactam antibiotics with SPase I inhibitors holds the potential to broaden the spectrum of β-lactams against MRSA and also reduce the emergence of resistant strains.
Potential SPase I inhibitors from in silico screens
In M. tuberculosis, although targeting LepB might potentially lead to eliminating persistent bacteria and shorten therapy, neither compound MD3 (used for target validation [56] ) nor arylomycin (due to the presence of resistance conferring Pro in its SPase I) can be currently pursued. Recently, a high-throughput virtual screening of 169,109 natural compounds (from the ZINC database; http://zinc.docking.org) using a model of the 3D structure of the M. tuberculosis SPase I, resulted in the identification of two different inhibitors EMP and PHM (see Supplementary Fig. S1 online) , which bind to the active site of the enzyme in silico Fig. 3 (continued) . [97] . Both EMP and PHM form hydrogen bond interactions with residues in the active site and substrate binding pockets. PHM forms a hydrogen bond with the nucleophilic Ser. The compounds are yet to be validated in vitro and for their antibacterial activity against M. tuberculosis.
SecA as an antibiotic target
3.1. SecA: properties, structure and mode of action; relevance as an antibiotic target and druggable sites 3.1.1. Properties, structure and mode of action SecA is a mechanoenzyme with an N-terminal ATPase domain and a C-terminal specificity domain (MW 102 kDa, in E. coli). The crystal structures of SecA from E. coli [98, 99] , M. tuberculosis [100] , B. subtilis [101] [102] [103] [104] [105] , T. maritima [103, 104] , T. thermophilus [106] , show a common structural and functional domain organization (Fig. 4) .
SecA is classified into the superfamily II (SF2) DEAD (DExH/D) proteins, which includes nucleic acid helicases [107, 108] . Functionally, helicases utilize energy from ATP hydrolysis to bind and unwind nucleic acid substrates, while SecA uses this chemical energy to bind and mobilize polypeptide substrates through the protein conducting channel. Structurally, both SecA and helicases contain two RecA-like subdomains with Walker A and B motifs [109] , that form the helicase or DEAD motor [108] . DEAD is the acronym for the conserved sequence-Asp-Glu-AlaAsp-in this family of proteins. The glutamate is the catalytic base that activates water for hydrolytic attack on ATP [110] and the aspartate ligates the Mg 2+ cofactor of ATP [109, 111] . In SecA the two subdomains are called nucleotide-binding domain (NBD) (Chatzi et al., in press, this volume) (Fig. 4) and IRA2 (intramolecular regulator of ATPase2). The ATPase active site in SecA is located at the interface of the two subdomains [112] . Recent biophysical data [111] show that a single electrostatic charge in the ATPase active site controls the global conformation of SecA. SecA also has two specificity domains, which distinguishes it from other SF2 proteins: the C-domain that is linked to IRA2 and the preprotein binding domain (PBD) which is rooted inside NBD. The C-domain contains 4 substructures: the long α-helical scaffold domain (SD); the conserved helix-loop-helix IRA1 switch (also known as two-helix finger); the α-helical wing domain (WD); and the C-terminal tail (C-tail) that binds Zn 2 + [105, 108] . The SD contacts all other domains of SecA, controls the opening and closing of the DEAD motor, and is involved in preprotein binding along with the PBD [113] ; IRA1 negatively regulates cytosolic SecA ATPase activity (in the resting state) [114] , makes important interactions with the SecYEG channel (during translocation) [115] and contains residues involved in SecA dimerization [116, 117] ; WD and the Ctail are involved in SecB and lipid binding [113] . The PBD contains an anti-parallel β-strand (stem) and a bilobate globular domain (bulb). The crystal structures show that the PBD bulb undergoes an approximately 75°swiveling motion between a 'closed' and an 'open' state (which could accommodate preproteins or regions of SecYEG) [108] . The movement of PBD creates two grooves on the surface of SecA: the large groove 1, formed between PBD, WD and SD is involved in signal peptide binding [116, 118, 119] and the expandable groove 2 (known as "the clamp"), created at the interface of PBD and IRA2, was proposed to bind mature regions of the preprotein [104] . Large-scale conformational changes of the PBD are expected to be required for initiation of the translocation process [120] .
SecA is a flexible enzyme, a property that aids its interaction with multiple ligands and also its motor function [104, 112, 121] . SecA interacts with nucleotides, preproteins, signal peptides [118] , SecB [122] and other chaperones, ribosomes [123] as well as other components (see below), all of which influence its activity [112] . Briefly, anionic phospholipids (phosphatidylglycerol and cardiolipin) are important for SecA binding to the membrane while nonlamellar-prone lipids (diacylglycerol and phosphatidylethanolamine) specifically enhance SecA binding to the bilayer. SecA binds to the membrane with low affinity at acidic phospholipids and with high affinity (low nM) at the SecYEG channel [112] . Binding of SecA to the various ligands and finally to the SecYEG-SecDFYajC complex allosterically stimulates the ATPase activity of SecA for driving the translocation process.
SecA-mediated targeting and secretory protein translocation across the E. coli inner membrane is detailed in Chatzi et al., in press (this volume). The mode of action of SecA, based on existing biophysical and biochemical data [108, 113] , is briefly outlined here: cytosolic SecA Recently, SecA has also been proposed to function alone as an ion and protein-conducting channel [124, 125] .
Relevance as antibiotic target
The factors that make SecA an attractive target are:
(i) SecA is ubiquitous and conserved in bacteria [25] .
(ii) It is essential for bacterial cell viability as demonstrated by constructing temperature-sensitive mutants of E. coli and B. subtilis [126] [127] [128] and by gene knockout technique in E. coli [129] . Growth of temperature-sensitive secA mutants at non-permissive temperatures (42°C) leads to defective protein secretion and cell division and finally to cell death [127, 128] . (iii) SecA or a homolog is absent from humans as confirmed by subtractive genomics approach [130] . (iv) SecA is a cytoplasmic target and a peripheral membrane protein.
Although any potential inhibitor needs to cross the membrane barrier(s), SecA should still be accessible to many compounds. During some stages of the catalytic cycle SecA is expected to have parts buried in the membrane [131] [132] [133] . The recent view of SecA functioning as an ion and protein conducting channel [124] also means that SecA might be more accessible for potential inhibitors. (v) SecA has several interactions and enzymatic activities, providing greater options for targeting. (vi) Targeting SecA will drastically reduce bacterial virulence since the newly synthesized virulence proteins that depend on SecAmediated protein transport will be locked up in an unfolded state within the bacterial membrane.
Mycobacteria and some Gram-positive bacteria (including Listeria, Staphylococcus and some Streptococcus species) possess two homologues of SecA called SecA1 and SecA2 (see review [134] ). In bacteria with two SecAs, the two enzymes have non-overlapping functions: SecA1 is the essential 'house-keeping' ATPase in the Sec-pathway (similar to SecA of E. coli and B. subtilis) while SecA2 is a nonessential ATPase, responsible for exporting a subset of proteins which are linked to virulence in many pathogens. Exceptions are C. glutamicum (nonpathogenic soil bacterium) and C. difficile (the major cause of nosocomial antibiotic-associated diarrhea), in which SecA2 is also essential [134] . The conservation of the functional domains across SecA (and SecA1) and SecA2, offers the possibility of developing inhibitors targeting both SecA proteins to inhibit growth as well as virulence [24] .
We confine our discussion to SecA (or SecA1) whose essentiality is confirmed in several bacteria including pathogens such as H. influenzae [135] , mycobacteria [136] , S. aureus [137] and Burkholderia pseudomallaei [138] . SecA is a broad-spectrum, druggable target [130] for which structural, biochemical and biophysical information, high-throughput screening assays and inhibitors are progressively evolving.
Druggable sites
SecA ATPase activity is essential for translocation [26] while SecA helicase activity is not essential for translocation in vivo. An obvious strategy is to find inhibitors of SecA ATPase activity. However, the nucleotide binding (DEAD motor) domain of SecA is conserved in other ATPases as well (e.g., ATP-dependent helicases, F1 ATPase, AAA ATPases and ABC transporters [111] ). Consequently catalytic inhibitors of SecA are likely to cross-react with other ATPases. This problem was encountered during early high-throughput screens [26] . Although catalytic inhibitors can be optimized by chemical modification, allosteric inhibitors that disrupt SecA ATPase activity by targeting regions other than those present in human ATPases offers better prospects [26] . In fact, most SecA inhibitors identified (Section 3.3) either compete with ATP binding or prevent ATP hydrolysis by binding to an allosteric site on SecA.
An alternate approach is to identify molecules that prevent SecAligand interactions, resulting in the inhibition of protein translocation. This area is currently unexplored and there are no inhibition assays specifically designed for this purpose. Two important interactions that could be targeted are SecA-SecYEG and SecA-preprotein interactions. The structures of SecA bound to nucleotide, SecYEG [103] a signal peptide and a tripeptide [104, 105, 119] as well as the increasing knowledge of the binding sites on SecA for interaction with these ligands [116, 139] , provide the basis for rational inhibitor design. Several pockets at the SecA surface are proposed as druggable sites in addition to the large groove 1 and a deep pocket formed by residues of the PBD and the Cterminal domain of SecA [130] . This is a unique approach as there are currently no drugs based on this type of interaction.
SecA inhibition assays
3.2.1. In vitro assays 3.2.1.1. ATPase activity assay. ATPase activity of SecA alone (basal/ intrinsic) or SecA with membrane (membrane ATPase) or SecA with membrane and preprotein (translocation ATPase), is commonly measured by colorimetric determination of the released phosphate using malachite green [140] . The SecA translocation ATPase assay, adapted to a 96-well format by researchers at Pfizer [141] , demonstrated the activity of SecA inhibitor, CJ-21,058 (Section 3.3.2). To simplify the in vitro ATPase assay for high-throughput inhibitor screening, a SecA mutant (Trp to Ala, at position 775, E. coli numbering) was designed with elevated intrinsic ATPase activity that supports normal protein translocation both in vitro and in vivo [142] . The use of the SecA mutant increases the sensitivity of the assay compared to the native SecA which has a low basal ATPase activity and in addition, obviates the need for membrane (inner membrane vesicles or proteoliposomes containing SecYEG) and unfolded preprotein components in the reaction mixture. The assay standardized in a 384-well format is robust (average Z′ factor [69] of 0.89), and led to the identification of novel 5-amino-thiazolo [4,5-d] pyrimidine inhibitors [143] (Section 3.3.2). Another screening assay utilized a truncated E. coli SecA devoid of the C-terminal regulatory domain-responsible for the low intrinsic ATPase activity-to identify fluorescein analogs as inhibitors [144] . The latter two screening assays are designed to identify active site inhibitors.
Preprotein translocation assay.
SecA-mediated translocation of unfolded preprotein substrates (e.g. alkaline phosphatase) in vitro A. tumefaciens [156] is monitored by SDS-PAGE followed by immunodetection [140] . Another gel-based assay involves 35 S-labeled proOmpA as a marker, which is quantified by densitometry [144, 145] . These assays are low-throughput and used as secondary assays to confirm SecA inhibition.
In vivo assays (target-based)
3.2.2.1. Whole cell reporter assay. A cell-based assay involving a recombinant E. coli strain with a SecA-LacZ fusion reporter system was developed by Wyeth-Ayerst Research for screening for SecA inhibitors [146] . The assay is based on the property of SecA to autogenously regulate its mRNA translation in response to changes in secretion levels. Under normal secretion conditions SecA binds to its own mRNA, inhibiting translation but when secretion is blocked, mRNA is released and translation is upregulated. One drawback is that the assay appears to preferentially select compounds that affect membrane integrity [146] .
Reduced expression of
SecA. An assay developed at Merck [147] utilizes an S. aureus strain that generates antisense RNA against secA thereby rendering the strain hypersensitive to inhibitors of SecA. A two-plate agar-based differential sensitivity screen-comparing the effect of compounds on the sensitized strain versus the wild-type control-conducted on a high-throughput scale led to the identification of the natural product inhibitor, pannomycin [147] (Section 3.3.3).
A common screen for Sec-pathway inhibitors.
A high throughput screening assay designed by Cowther et al. [148] utilizes a recombinant E. coli strain that accumulates β-galactosidase (β-gal) in its cytoplasm if translocation through SecYEG is blocked. Presumably, toxic compounds and nonspecific protein synthesis inhibitors prevent β-gal production and do not show up as hits. Although, an initial screen of 800 compounds did not yield reproducible hits, the assay is reliable (average Z′ factor of 0.60, manual screen) and suited for 384-well format.
Overview of SecA inhibitors
The different approaches (in vitro, in vivo and in silico) for finding SecA inhibitors have resulted in only a few molecules, described below.
Discovery of sodium azide, a research tool for SecA inhibition studies
Sodium azide was the first SecA inhibitor reported (in 1990s), although its antibacterial activity was known since the late 19th century [130] . Sodium azide inhibits translocation ATPase activity (but not intrinsic ATPase activity) of SecA [ Table 5 , compound 1], probably by blocking the de-insertion step and trapping SecA in the membrane [132, 149] . Sodium azide also inhibits other ATPases including mitochondrial F-ATPase [150] and several enzymes including cytochrome c oxidase, superoxide dismutase and alcohol dehydrogenase [151] and is unsuitable as an antibiotic. Nevertheless, the azide inhibitor demonstrated SecA as an antibacterial target and has served as a positive control in SecA inhibition assays [141, 142, 146, 148] .
The exact mechanism by which sodium azide works as a SecA inhibitor is not known. Based on the mechanism of inhibition of the mitochondrial F-ATPase by sodium azide, a comparison can be drawn [130] . The ternary structure of the complex of F 1 -ATPase with ADP and azide [150] , shows that the azide anion brings the side chains of two catalytically essential amino acids closer to the nucleotide, creating a tighter fit with the ADP molecule and stabilizing the ADP-bound state. Since SecA and F 1 -ATPase bind to adenine nucleotides with a very similar geometry [105] , a comparable mechanism could explain how sodium azide stabilizes the membrane-inserted, ATP-bound state of SecA [131, 132] .
Discovery of equisetin (CJ-21,058), thiazolo[4,5-d]pyrimidine and fluorescein analogs by the in vitro approach
The first natural product inhibitor of SecA, CJ-21,058, isolated from an unidentified fungus, is an analog of Fusarium toxin equisetin, with a hydrophilic tetramic acid moiety and a hydrophobic bicyclic moiety [141] . CJ-21,058 (Table 5 , compound 2) inhibits translocation ATPase activity of E. coli SecA (IC 50 of 15 μg/ml), as demonstrated in an in vitro assay developed by Pfizer (see Section 3.2.1.1). The inhibitor is antibacterial against multi-drug resistant S. aureus and Enterococcus faecalis (MIC 5 μg/ml) while it has no activity against E. coli and Streptococcus pyogenes. The correlation between SecA inhibition and antibacterial activity and the effect of CJ-21,058 on the intrinsic ATPase activity of SecA was not reported [141] . Docking of CJ-21,058 into the active site of E. coli SecA shows that the molecule binds at the ATP binding site, indicating that it probably competes with ATP for binding [144] .
We undertook a high-throughput screen of~27,000 diverse smallmolecules against E. coli SecA mutant with elevated intrinsic ATPase activity (Section 3.2.1.1) [142] . This led to identifying several inhibitors belonging to different chemical classes, including nipecotic acid derivatives and pyrrolopyrimidines with IC 50 values ranging from 50 to 150 μM against wild-type E. coli SecA [130, 142] . A further screen of a library of synthesized thiazolo [4,5-d] pyrimidine derivatives, identified several ATPase inhibitors of E. coli and S. aureus SecA1 [143] . Kinetic analysis of the most potent inhibitor (Table 5 , compound 3) revealed a mixed-type inhibition, with an inhibition constant of 60 μM against translocation ATPase activity of S. aureus SecA1 [130] . The antibacterial activity was not significant (unpublished data).
Fluorescein analogs (hydroxanthenes), Rose Bengal and Erythrosin B (Table 5 , compounds 4 and 5), identified from an in vitro screen employing truncated unregulated E. coli SecA (Section 3.2.1.1), proved effective inhibitors with IC 50 of 0.5 and 2 μM, respectively [144] . Rose Bengal is relatively more potent than Erythrosin B, also against the full-length (regulated) SecA from E. coli and B. subtilis, as seen in Table 5 . Rose Bengal strongly inhibits the preprotein translocation Notes to Table 5: NR698 is a permeable leaky mutant of E. coli. ND: not determined. ]pentadeca-1(11),3,5,7-tetraen-9-ium. a IC 50 in vitro with IC 50 of about 0.25 μM (the highest potency among the SecA inhibitors). While the inhibitor lacks antibacterial activity against the wild-type E. coli, it has equally potent antibacterial activity against a permeable leaky E. coli mutant (NR698) and wild-type B. subtilis (IC 50 of 3.1 μM). Thus, the fluorescein analogs are more effective on Gram-positive bacteria for which outer membrane permeability is not a problem [144] . It is interesting to note that unlike sodium azide, Rose Bengal and Erythrosin B inhibit all three ATPase activities of SecA (basal, membrane and translocation), albeit with different efficiencies as observed in Table 5 . An in silico modeling study shows that the fluorescein inhibitors bind at the high affinity ATP-binding site on SecA and that Rose Bengal and the SecA inhibitor, CJ-21,058 occupy the same position with the same orientations [144] . Huang et al. [144] indicate that Rose Bengal and Erythrosin B are competitive inhibitors against ATP and are likely to be general ATPase inhibitors which are more effective on the catalytic SecA ATPase.
A recent SAR study indicates that the xanthene ring in Rose Bengal is essential for activity and that simplified analogs with half the molecular weight of Rose Bengal can be as potent as the parent compound [152] .
Discovery of Pannomycin by the in vivo approach
Pannomycin (a substituted cis-Decalin) is a secondary metabolite from the fungus, Geomyces pannorum, identified in a SecA two-plate differential sensitivity antisense assay (Section 3.2.2.2) by researchers at Merck [147] . Pannomycin was one among over 115,000 natural product extracts (derived from both actinomycetes and fungi) screened in the high-throughput antisense assay, which had a primary hit rate of 0.1%. Pannomycin [ Table 5 , compound 6] is structurally similar to the SecA inhibitor CJ-21,058, which is comprised of decalin linked to a tetramic acid. Pannomycin has a weak antibacterial activity (in mM range) against Gram-positive S. aureus Smith strain, E. faecalis and B. subtilis as shown in Table 5 , but not against S. pneumoniae, H. influenzae, E. coli and Candida albicans. Parish et al. [147] attribute the higher antibacterial activity of CJ-21,058 to the presence of tetramic acid and suggest further optimization of the pannomycin decalin scaffold. However, the SecA inhibitory activity of pannomycin has not been further validated and its mode of action remains unclear.
The antisense screening assay is highly sensitive which is reflected by the fact that it could identify a weak inhibitor such as pannomycin. An earlier attempt at high-throughput screening using a SecA-LacZ reporter fusion system (Section 3.2.2.1) identified a few molecules that induced SecA expression (which occurs when secretion is blocked) but all the hits were found to have a deleterious effect on the membrane [146] . The most potent hit is shown in Table 5 (compound 7).
Discovery of inhibitors of SecA (of E. coli and Candidatus Liberibacter asiaticus) by an in silico approach
The availability of the crystal structure of E. coli SecA [98] , enabled in silico screening of compounds against SecA. Structure-based virtual screening involves docking of compounds (from an entire library or database) into the active site or binding pocket and estimating theoretical binding energies. Based on these, compounds are selected for in vitro testing [151, 153] . Screening of 60,000 compounds from a commercial collection (MayBridge database, UK) against E. coli SecA holo-form (PDB ID: 2FSG), identified 31 hits of which the two best compounds SEW-05929 and HTS-12302 (IC 50 of 100 μM in each case) [151, 154] are shown in Table 5 [compounds 8 and 9]. Further optimization led to more potent thiouracil derivatives of the parent compound, HTS-12302 [154] . As seen in Table 5 [compounds 10, 11 and 12], the thiouracil derivatives inhibit the intrinsic ATPase activity of the full-length E. coli with IC 50 values in the range of 20 to 60 μM. They are highly potent against the truncated E. coli devoid of C-terminal regulatory domain. However, the compounds do not have significant biological activity against the wild-type E. coli, except compound 12 [ Table 5 ] which has some antibacterial activity against NR698 [154] .
Interestingly, another structure-based virtual screen was directed towards finding SecA inhibitors of (Gram-negative bacterium) Candidatus Liberibacter asiaticus, the causal agent of Huanglongbing disease of citrus [155] . In this work, a 3D homology model of Ca. L. asiaticus SecA was built based on the crystal structure of E. coli SecA (PDB ID: 2FSG) [98] . A total of 5,016 small-molecules, filtered based on physicochemical properties from ChemBridge and Specs chemical databases, were used for molecular docking into the active ATP-binding site of Ca. L. asiaticus SecA. Among the 20 hits selected for biological activity studies, the highest potency (IC 50 of 2.5 μM against Ca. L. asiaticus SecA) was observed for compound 13, Table 5 [155] . The antimicrobial activity is not known.
Wang et al. [156] , further optimized the homology model of Ca. L. asiaticus SecA using three PDB structures (2VDA, 2FSF and 2FSG) as templates and virtually docked 20000 compounds from the commercially available ZINC database. Twenty compounds were selected based on their predicted binding to SecA and tested in vitro for their inhibitory activity. Five of these molecules (Table 5 , compounds 14 to 18) were found to inhibit the intrinsic ATPase activity of Ca. L. asiaticus SecA at nanomolar concentrations (IC 50, 0.25-0.92 μM). The inhibitors show antimicrobial activity against Agrobacterium tumefaciens, which is phylogenetically related to Ca. L. asiaticus, although at a high concentration (see Table 5 ). While there is a potential to optimize these molecules towards developing antimicrobial agents against Ca. L. asiaticus, it would also be interesting to know their spectrum of activity against other bacterial pathogens.
Recently, a 3D-Quantitative Structure-Activity Relationship (3D-QSAR) model was developed using known SecA inhibitors [157] . As the numbers of SecA inhibitors increase, such models could facilitate virtual screening and compound optimization.
All three approaches used for SecA inhibitor screening have been fruitful in finding effective inhibitors. In the case of SecA, as many effective inhibitors (in vitro) lack antibacterial activity especially against Gram-negative bacteria, it is tempting to infer that the in vivo approach holds greater promise in finding novel antibacterials.
In brief: attempts to target other protein secretion channels/components
The three enzymes, SPase II, SPase IV and YidC, the twin-arginine translocation pathway and the Type I to VI secretion systems, are already being evaluated as novel targets. These components/pathways are detailed in other articles in this issue, while this section focuses on their possible use as antibacterial targets.
Targeting the lipoprotein (or Type II) signal peptidase
SPase II or the lipoprotein signal peptidase (LspA) is responsible for processing lipoproteins (diacylglyceryl modified proteins). The recognition and cleavage site of LspA lies in a region known as the lipobox, present in the C-region of the signal peptide. The consensus sequence of the lipobox in B. subtilis and E. coli is L-A/S-A/G-C. Processing by LspA occurs just before the invariable cysteine residue that is also the site of diacylglyceryl modification [22] . LspA is a potential antibiotic target because: LspA is an unconventional aspartic acid protease which lacks the conserved Asp-Thr/Ser-Gly motif present in (eukaryotic and viral) aspartic proteases [158] . LspA is absent in eukaryotic cells [14] , essential for viability in Gram-negative bacteria such as E. coli but not in Gram-positive bacteria such as B. subtilis [158] or Lactococcus lactis [159] . However, in pathogens including M. tuberculosis, LspA plays an important role in processing virulence determinants. An LspA mutant in (Gram-positive, acid-fast) M. tuberculosis, is severely attenuated in virulence tuberculosis models [160] . The active site is accessible to exogenously added potential inhibitors. In B. subtilis LspA, the catalytic residues are placed on the extracytoplasmic side, just below the membrane surface [158] .
Although LspA has not been characterized in great detail and no high-throughput assays are reported yet, at least two effective natural product inhibitors (Table 6 , row 1) are known to block its activity. Globomycin, a cyclic peptide antibiotic [161] and its synthetic derivatives [162] inhibit SPase II in a non-competitive manner and are bactericidal against enteric Gram-negative bacteria e.g., E. coli. Recently, Myxovirescin/Megovalicin/M-230B, a macrocyclic metabolite (polyketide) produced by myxobacteria, was shown to target LspA with 2 to 10 fold better whole cell activity (E. coli MG1655, MIC = 4 μg/ml) compared to Globomycin (E. coli MG1655, MIC = 8 μg/ml) [163] . It has broad-spectrum antibacterial activity and is non-toxic to eukaryotic cells, including human cells. Synthesis of Globomycin [164] as well as Myxovirescin A 1 [165, 166] , has paved the way for SAR studies. The basic questions that remain to be addressed are: could these inhibitors lead to effective drugs? What is the structure of the active site? How different is the structure of LspA in Gram-positive and Gram-negative bacteria? Why is the enzyme essential in some bacteria, but not in others?
4.2. Targeting the Type IV prepilin peptidase (Type IV signal peptidase) Type IV signal peptidases-identified in several Gram-negative bacteria and an increasing number of Gram-positive bacteria-play an essential role in processing the precursors of Type IV pilin (surface structures often involved in virulence) and prepilin-like proteins (secretory proteins which possess a Type IV signal peptide, but are not pilin subunits) [167] . The Type IV SPases span the membrane eight times, have their active site residues close to the membrane boundaries and cleave their substrates within the cytoplasm, just proximal to the membrane surface [22] . The substrate recognition and cleavage site of the SPase IV differ from that of SPases I and II. SPase IV cleaves between the residues Gly and Phe in a conserved region located between the N and H regions of the signal peptide. It is a bifunctional enzyme, also responsible for N-methylation of the Phe at position + 1 relative to the cleavage site [22] .
Type IV SPase is considered an antivirulence target. The enzyme plays a central role not only in Type IV pilus biogenesis but also in toxin and other enzyme secretion, natural competence, DNA transfer and biofilm formation [168] . Marsh and Taylor [169] demonstrated that mutation of the V. cholerae SPase IV gene attenuates virulence in vivo. SPase IV does not have eukaryotic counterpart. It is an unusual aspartic acid protease which differs from the majority of aspartic acid proteases in that the active site aspartic acids are not found in the D(T/S)G motif and the pH optimum for in vitro activity is near neutral as opposed to acidic (pH 2-4) [167] . The active site of the enzyme is accessible to inhibitors [167] .
Resistant to the classical protease inhibitors (including pepstatin, a general aspartic acid inhibitor), Type IV signal peptidase is inhibited by a combination of EDAC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and glycinamide (known to inhibit non-pepsin-like acid proteases) [167] . Rationally designed peptides, mimicking the cleavage site region of its native substrate inhibit the cleavage activity of Type IV signal peptidase in vitro [170] . Chemical inhibitors of SPase IV, identified by in vitro screening include Voltaren (IC 50~1 10 μM) and γ-secretase inhibitor VI (IC 50~5 00 μM) ( Table 6 , row 2), among others [170] .
Search for potent inhibitors, a detailed understanding of the characteristics of the enzyme, structure, and distribution (presence/absence in different bacterial species) will help in further evaluating SPase IV as a target.
Targeting YidC (Sec-dependent or independent) membrane protein insertion
In the case of membrane proteins, the hydrophobic transmembrane segment region in the nascent protein serves as the signal for targeting and insertion into the membrane. These proteins are routed to the SecYEG translocase by Signal Recognition Particle (SRP)-mediated cotranslational targeting [171] . Presumably, a lateral gate in the SecYEG channel allows membrane protein insertion with the help of YidC which is positioned close to the channel gate [172] . YidC is an integral membrane protein that assists in the lateral insertion and assembly of membrane proteins into the lipid bilayer via the Sec-translocase, but can also independently function as an insertase (see review [173] ). YidC is essential for cell viability [174] . While Gram-negative bacteria have one YidC, most Gram-positive bacteria have two YidC homologs (YidC1 and YidC2) [171] . Deletion of both homologs was shown to be lethal in B. subtilis [175] . YidC homologs are also present in mitochondria (Oxa1 and Oxa2) and chloroplasts (Alb3) but absent in ER and plasma membrane of eukaryotes [176] . The YidC/Oxa/Alb3 members share conserved hydrophobic regions comprising 5 transmembrane domains, representing the catalytically active part [171] . Partial functional complementation has been demonstrated between the homologs Oxa 1 and YidC 2 [176] as well as between Oxa2 and YidC1/YidC [177, 178] . Although the YidC/Oxa/Alb3 family has a common ancestry, the homologs in bacteria and mitochondria have evolved independently [176] . Given Twin-arginine translocation (Tat) Primary screen measures the extracellular activity of phospholipase C (a potent toxin and a Tat-dependent secretion product) in P. aeruginosa. Several follow-up assays to evaluate Tat-functionality in vivo N-phenyl maleimide (one of the two potent inhibitors identified) [186] 5. Type II secretion system The primary bioluminiscent reporter screen uses a P. aeruginosa strain responsive to SecA depletion or inhibition. Secondary assays (β-lactamase, phospholipase C and elastase secretion) identify Sec/Tat/Type II inhibitors.
5,7-dichlorohydroxyquinoline, one among the 9 inhibitors effective against P. aeruginosa and Burkholderia pseudomallei [194] 6. Type III secretion system Luciferase reporter gene assay in Yersinia pseudotuberculosis Salicylidene acylhydrazides, effective against Y. pseudotuberculosis with broad-spectrum activity against Gram-negative bacteria (e.g., Chlamydia, Shigella, and Salmonella species) [190, 195] 7. Type IV secretion system In vivo assay that measures interaction of Brucella VirB8 (an inner membrane protein) with itself and other components of the Type IV secretion apparatus. VirB8 is an essential and conserved component of the Type IV secretion system.
Inhibitor (B8I-2), belongs to salicylidene acylhydrazide class of molecules, active against Brucella abortus.
[ 196, 197] the homology, whether YidC can be selectively inhibited without any harm to human cells, needs further investigation. A recent study utilized an antisense RNA-mediated, yidC downregulated E. coli strain to identify two antibacterial essential oils (eugenol and carvacrol) that possibly targets YidC [179] (Table 6 , row 3). The mode of action of the molecules is not known. Currently, no other inhibitors or assays are reported for this target. In addition, knowing the exact molecular mechanism by which YidC operates or interacts, a subject of ongoing research [174] , will contribute greatly to this line of work.
Targeting the twin-arginine translocation pathway
The Tat-pathway, which uniquely transports folded proteins across the cytoplasmic membrane, operates in many bacteria. The Tat-pathway gets its name from two highly conserved arginine residues in the signal peptide region of the protein, recognized by the Tat-apparatus for membrane targeting and transport. The Tat-system is comprised of either three or two essential integral membrane components, TatABC (as in Gram-negative E. coli) or TatAC (as in Gram-positive Bacillus), respectively [180, 181] . The in vitro data suggests that the subsequent steps in Tat-mediated transport in E. coli are: binding of the signal peptide region of the preprotein to TatC which forms a complex with TatB, translocation of the protein through a channel of varying size formed by TatA oligomers and release of the mature protein after removal of SP by the SPase I. The translocated proteins are subsequently released into the extracellular environment (in Gram-positive bacteria) or into the periplasm (in Gram-negative bacteria) for further transport across the outer membrane and, where applicable, outside the cell via the Type II secretion system [182] . The Tat-pathway is identified as an antivirulence target because several bacterial pathogens (e.g., M. tuberculosis, L. pneumophila, P. aeruginosa and B. pseudomallei) utilize the Tat-pathway for transporting extracellular enzymes and other virulence determinants essential for pathogenesis [183] . The Tat-system is also functional in plants but no homologues are seen in animals. In P. aeruginosa, a tatC mutant is severely attenuated in a rat pulmonary infection model [184] , while in M. tuberculosis, the Tat-pathway is seemingly essential for growth, at least under standard laboratory conditions [185] .
Recently, a high-throughput assay developed for screening inhibitors of the Tat-pathway identified two compounds that directly affect its function [186] (Table 6 , row 4). The current limitation of the Tatpathway as a novel target is the lack of detailed structural and functional data across different bacterial species due to the relatively recent history of its discovery (in the mid-nineties). Moreover the Tat-pathway is present in some but not all bacteria, which narrows down its spectrum.
The Tat-pathway is dependent on the Type I SPase for processing and release of its preproteins from the membrane [187] . Thus targeting SPase I will also disrupt the Tat-mediated protein secretion.
Targeting the Type I to VI secretion systems in Gram-negative bacteria
Protein secretion in Gram-negative bacteria is either a one-step or two-step process. In the latter case, the proteins first cross the inner membrane (via the Sec-pathway or in some cases, the Tat-pathway) and then cross the outer membrane to reach the external environment. Gram-negative bacteria possess at least six specialized secretion systems (Type I to VI), of which Type II and Type V are terminal branches of the Sec-pathway while the others export proteins directly from the cytoplasm to the outside milieu or even into the eukaryotic host cells (see review [188] ). These secretion systems are required for transport of proteins essential for pathogenesis (e.g., toxins, enzymes, anti-host factors), biofilm formation, and interaction with host or nutrient acquisition, and hence, are good anti-virulence targets [189] , but are not essential for viability. Components of the Type II, Type III and Type IV secretion systems are already pursued as targets and this line of work resulted in high-throughput screening and identification of inhibitors of the secretion systems (Table 6 , rows 5 to 7). We refer the interested reader to [190] [191] [192] for detailed reviews on the targeting of secretion systems for bacterial virulence inhibitors. It must be noted that the components that make up the Type I to VI secretion apparatus are inserted into the membrane or exported by the Sec-system [22] , and hence, targeting the Sec-pathway would also render these secretion systems defunct.
The alternative approach of using antivirulence targets to disarm bacteria and contain infection also looks promising. However, the challenges of exploiting them in monotherapy or combination therapy will only become clear once the inhibitors are developed into drugs.
Concluding remarks
The Sec-pathway components, SPases I and SecA are universal, conserved and essential in bacteria and can be differentially targeted without significant harm to humans or animals. They are characterized and validated targets in non-pathogenic as well as pathogenic bacteria including E. coli, S. aureus, P. aeruginosa and M. tuberculosis. Different approaches have been applied to discover SPase I and SecA inhibitors, for over two decades. We have witnessed a transition in the approach from random high-throughput screening using the isolated enzyme to whole cell antibacterial or target-based whole cell screening. SPase I inhibitors, arylomycins (including actinocarbasin) and krisynomycin are good starting points for optimization towards novel antibacterials. SPase I, being a single-enzyme target, can evolve resistance by pointmutation. Preclinical assessment of resistance development is important while evaluating new drug leads based on SPase I. SPases I can also be exploited in combination therapy as demonstrated by synergy of SPase I inhibitors with β-lactams and an aminoglycoside, gentamicin. This idea is further supported by the observation that the SPase I inhibitor, M131, in combination with Imipenem suppresses emergence of resistance. There are currently no antibacterial candidates targeting SecA. Although a few effective active site inhibitors have been identified using in silico, in vitro and in vivo approaches, allosteric inhibitors with good antibacterial properties are desirable. Assays specifically designed for finding SecA inhibitors that block its interaction with SecYEG and or preproteins might be beneficial. Despite several crystal structures of SecA and continuing efforts, its mode of action is not completely understood. The availability of high-resolution crystal structures especially that of SecA actively engaged in translocation of preprotein in the protein conducting channel could fine tune the in silico approach for screening or optimizing the identified molecules. Similarly, crystal structure of the full length SPase I including that from Gram-positive bacteria will be helpful. The Tat-pathway and the bacterial secretion systems-Type II, Type III and Type IV-have been pursued as antivirulence targets, resulting in a few inhibitors. In comparison with SPase I or SecA, these targets are not necessarily broad-spectrum and are not bactericidal. In addition, targeting the SPase I will disrupt the Tat-pathway and the terminal branches of the Sec-pathway (Type II and Type V secretion systems), while targeting SecA will either disrupt or severely affect the additional (Type I to Type VI) secretion systems. The Sec-pathway components, YidC, SPase II and SPase IV are also valid targets which need further work. In essence, the Sec-pathway does offer some good targets for novel antibacterial research.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bbamcr.2014.02.004.
